Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
Sign Up to like & getrecommendations! Published in 2023 at "Transplantation Direct"
DOI: 10.1097/txd.0000000000001419
Abstract: Background. Compared with calcineurin inhibitor–based immunosuppression, belatacept (BELA)-based treatment has been associated with better renal function but higher acute rejection rates. This phase 2 study (NCT02137239) compared the antirejection efficacy of BELA plus everolimus (EVL)… read more here.
Keywords: tac mmf; acute rejection; bela evl;